Lido Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Lido Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$237K	Buy	+1,254	New	+$219K	﹤0.01%	1692
2018 Q4	–	Sell	-3,555	Closed	-$597K	–	460
2018 Q3	$597K	Buy	3,555 +40	+1%	+$6.88K	0.06%	211
2018 Q2	$605K	Buy	3,515 +84	+2%	+$13.7K	0.07%	170
2018 Q1	$518K	Buy	3,431 +220	+7%	+$32.3K	0.07%	181
2017 Q4	$432K	Hold	3,211	–	–	0.06%	173
2017 Q3	$454K	Buy	+3,211	New	+$486K	0.07%	155

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Lido Advisors's JAZZ Position: Q1 2026 in Review

Lido Advisors opened a new position in Jazz Pharmaceuticals (JAZZ) in Q1 2026: 1,254 shares worth $237K. The stake represents ﹤0.01% of the portfolio and ranks #1692 among its holdings. This is a return to the name: Lido Advisors previously reported a position in JAZZ as recently as Q3 2018.

Lido Advisors first reported a position in JAZZ in Q3 2017 and has held it in 6 quarters since. The position peaked at $605K in Q2 2018. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Lido Advisors held 1,254 shares of Jazz Pharmaceuticals worth $237K as of Q1 2026.
Jazz Pharmaceuticals was a new Lido Advisors position in Q1 2026.
Jazz Pharmaceuticals made up ﹤0.01% of Lido Advisors's portfolio in Q1 2026, its #1692 holding.
Lido Advisors first reported a position in Jazz Pharmaceuticals in Q3 2017 and has held it in 6 quarters since.
Lido Advisors's Jazz Pharmaceuticals position peaked at $605K in Q2 2018.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Lido Advisors's 13F filing for Q1 2026, filed 13 May 2026.